Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiate ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...

Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading. On February 2, 2026, Clear Street began covering Caribou Biosciences, Inc.

Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsSteven Harr - President, CEO ...

Cancer is one of the most serious health problems in the world. Every year, millions of people are diagnosed with different ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...